Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Universal CAR T Cells for the Treatment of Acute Myeloid Leukemia
NCT05995041Phase 1Not yet recruiting
- Sponsor
- Shenzhen Geno-Immune Medical Institute
- Start
- Jun 2027
- Primary completion
- Dec 2029
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of REVO-UWD-03 in acute myeloid leukemia (AML), sponsored by Shenzhen Geno-Immune Medical Institute. Primary endpoint: Safety of infusion at 6 months. Planned start Jun 2027; status: not yet recruiting.
02
Drugs
REVO-UWD-03
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05995041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05995041.